Table 3.

Best overall response to avadomide by investigator assessment per tumor type and cohort

Best response, n (%)Avadomide (0.5 mg)Avadomide (1.0 mg)Avadomide (1.5 mg)Avadomide (2.0 mg)Avadomide (2.5 mg)Avadomide (3.0 mg)Avadomide (3.5 mg)Overall
All patients(n = 3)(n = 4)(n = 3)(n = 3)(n = 6)(n = 8)(n = 7)(n = 34)
Other solid tumor(n = 3)(n = 2)(n = 2)(n = 2)(n = 2)(n = 4)(n = 4)(n = 19)
 SD2 (67)001 (50)1 (50)01 (25)5 (26)
 PD1 (33)2 (100)2 (100)1 (50)1 (50)3 (75)1 (25)11 (58)
 Not evaluable000001 (25)2 (50)3 (16)
HCC(n = 1)(n = 1)(n = 2)
 SD1 (100)1 (100)2 (100)
Brain cancer(n = 1)(n = 2)(n = 1)(n = 2)(n = 6)
 Nonprogression1 (100)1 (50)1 (100)2 (100)5 (83)
 Progression01 (50)001 (17)
NHL(n = 1)(n = 3)(n = 1)(n = 5)
 CR01 (33)01 (20)
 PR01 (33)1 (100)2 (40)
 PD01 (33)01 (20)
 Not evaluable1 (100)001 (20)
MM(n = 1)(n = 1)(n = 2)
 SD1 (100)01 (50)
 PD01 (100)1 (50)
  • Abbreviations: MM, multiple myeloma; PD, progressive disease; SD, stable disease.